Effet du golimumab en intraveineuse sur la fatigue et relation avec la réponse clinique chez les adultes atteints de spondylarthrite ankylosante active dans l'étude de phase 3 GO-ALIVE
Rheumatol Ther. 2023;10(4):983–999 doi 10.1007/s40744-023-00556-y
Administration of IV-golimumab 2 mg/kg improves fatigue symptoms in axial spondylitis in a 52 Week study. At Week 16 of treatment, improvements in ASAS, ASDAS, BASDAI and SF-36 scores were observed at week 16 of treatment.